| BEONE-MEDICINES-LTD |
BEONE-MEDICINES-LTD |
92%
|
Under the BeOne Agreement, the Company is eligible to receive tiered royalties of mid-single to mid-double digit percentages on annual net sales of Ziihera in Asia (other than Japan), Australia and N… |
| JAZZ-PHARMACEUTICALS-IRELAND-LIMITED |
JAZZ-PHARMACEUTICALS-IRELAND-LIMITED |
92%
|
Under the BeOne Agreement, the Company is eligible to receive tiered royalties of mid-single to mid-double digit percentages on annual net sales of Ziihera in Asia (other than Japan), Australia and N… |
| DAIICHI-SANKYO |
DAIICHI-SANKYO |
90%
|
The decrease in total revenue was driven mainly by the achievement of non-recurring clinical milestone payments in 2025 of $14.0 million and $3.1 million from GSK and Daiichi Sankyo, respectively |
| BMY |
Bristol-Myers Squibb Company |
85%
|
payments and royalties on potential future product sales we may receive. Importantly, these partnerships include predominantly non-target-exclusive licenses for any of our therapeutic platforms, so w… |
| BMY |
Bristol-Myers Squibb Company |
85%
|
Reciprocal relationship from BMY graph: Reciprocal relationship from ZYME graph: payments and royalties on potential future product sales we may receive. Importantly, these partnerships include predo… |
| BMYMP |
Bristol-Myers Squibb Co |
85%
|
payments and royalties on potential future product sales we may receive. Importantly, these partnerships include predominantly non-target-exclusive licenses for any of our therapeutic platforms, so w… |
| BMYMP |
Bristol-Myers Squibb Co |
85%
|
Reciprocal relationship from BMYMP graph: Reciprocal relationship from ZYME graph: Reciprocal relationship from BMYMP graph: Reciprocal relationship from ZYME graph: payments and royalties on potenti… |
| CELGENE-ALPINE-INVESTMENT-CO-LLC |
CELGENE-ALPINE-INVESTMENT-CO-LLC |
85%
|
payments and royalties on potential future product sales we may receive. Importantly, these partnerships include predominantly non-target-exclusive licenses for any of our therapeutic platforms, so w… |
| JAZZ |
Jazz Pharmaceuticals plc |
85%
|
Reciprocal relationship from JAZZ graph: Reciprocal relationship from ZYME graph: Reciprocal relationship from JAZZ graph: Reciprocal relationship from ZYME graph: Reciprocal relationship from JAZZ g… |
| JAZZ |
Jazz Pharmaceuticals plc |
85%
|
: $ , 2022: $ ) in research and development expense and general and administrative expense accounts. As of December 31, 2024, the total amount contributed by ESPP participants and not yet settled is … |
| BEONE |
BEONE |
80%
|
These decreases were partially offset by higher royalty revenue from Jazz and BeOne in 2026 |
| JNJ |
Johnson & Johnson |
72%
|
Reciprocal relationship from JNJ graph: Reciprocal relationship from ZYME graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from ZYME graph: Reciprocal relationship from JNJ grap… |
| JNJ |
Johnson & Johnson |
72%
|
ne Medicines Ltd. (previously known as BeiGene, Ltd.) (“BeOne”): Milestone revenue Recognition of deferred revenue Drug supply Development support payments Royalties Johnson & Johnson Innovative Medi… |
| SNYNF |
Sanofi |
72%
|
our partnered product candidates, one or more of our U.S. patents may be eligible for limited patent term extension under the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent term… |
| SNYNF |
Sanofi |
72%
|
Reciprocal relationship from SNYNF graph: Reciprocal relationship from ZYME graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from ZYME graph: our partnered product candidates,… |
| BEIGENE-LTD |
BEIGENE-LTD |
62%
|
and administrative support, as well as by raising capital, conducting business planning and protecting our intellectual property. Other than the receipt of royalties on sales of zanidatamab and regul… |
| CAPITAL-RESOURCES |
CAPITAL-RESOURCES |
62%
|
istorically, we have devoted substantially all of our financial resources and efforts to developing our proprietary therapeutic platforms, identifying potential product candidates and conducting prec… |
| CATALYST-PHARMS-INC |
CATALYST-PHARMS-INC |
62%
|
ock. Risks Relating to Our Partnerships We depend on our collaborative relationships with Jazz, BeOne and J&J to further develop and commercialize zanidatamab and other product candidates, and if our… |
| DAIICHI-SANKYO-CO-LTD |
DAIICHI-SANKYO-CO-LTD |
62%
|
he China National Medical Products Administration (“NMPA”) to seek approval for zanidatamab for the first-line treatment for HER2+ locally advanced or metastatic GEA, including cancers of the stomach… |
| DOHME-RESEARCH-GMBH |
DOHME-RESEARCH-GMBH |
62%
|
he China National Medical Products Administration (“NMPA”) to seek approval for zanidatamab for the first-line treatment for HER2+ locally advanced or metastatic GEA, including cancers of the stomach… |
| GLAXOSMITHKLINE-INTELLECTUAL-PROPERTY-DEVELOPMEN |
GLAXOSMITHKLINE-INTELLECTUAL-PROPERTY-DEVELOPMEN |
62%
|
he China National Medical Products Administration (“NMPA”) to seek approval for zanidatamab for the first-line treatment for HER2+ locally advanced or metastatic GEA, including cancers of the stomach… |
| GSK |
GSK plc |
62%
|
Reciprocal relationship from GSK graph: Reciprocal relationship from ZYME graph: Reciprocal relationship from GSK graph: Reciprocal relationship from ZYME graph: he China National Medical Products Ad… |
| JAZZ-PHARMACEUTICALS-INC |
JAZZ-PHARMACEUTICALS-INC |
62%
|
. The remaining unamortized compensation expense as of March 31, 2026 will be recognized over a weighted-average period of 1.85 years. 9. Research, Collaboration and Licensing Agreements Revenue reco… |
| NASDAQ-STOCK-MARKET-LLC |
NASDAQ-STOCK-MARKET-LLC |
62%
|
onduct that are not in compliance with our policies and procedures, which, regardless of the ultimate outcome, may result in adverse publicity that could materially harm our brand, reputation and bus… |
| PROTECT-TUMOR-SPECIFIC-IMMUNE-CO |
PROTECT-TUMOR-SPECIFIC-IMMUNE-CO |
62%
|
he China National Medical Products Administration (“NMPA”) to seek approval for zanidatamab for the first-line treatment for HER2+ locally advanced or metastatic GEA, including cancers of the stomach… |
| ROYALTY-PHARMA-DEVELOPMENT-FUNDING-LLC |
ROYALTY-PHARMA-DEVELOPMENT-FUNDING-LLC |
62%
|
he China National Medical Products Administration (“NMPA”) to seek approval for zanidatamab for the first-line treatment for HER2+ locally advanced or metastatic GEA, including cancers of the stomach… |
| USA-LLC |
USA-LLC |
62%
|
tents Results of Operations for the Three Months Ended March 31, 2026 and 2025 Revenue Three Months Ended March 31, Increase/ (Decrease) (dollars in millions) 2026 2025 Revenue from research and deve… |
| ZYMEWORKS-BC-INC |
ZYMEWORKS-BC-INC |
62%
|
inancial instruments. All marketable securities are classified as available-for-sale and are recorded at fair value (note 5). Concentration of Credit Risk Financial instruments that potentially subje… |
| ZYMEWORKS-EXCHANGECO-LTD |
ZYMEWORKS-EXCHANGECO-LTD |
62%
|
onduct that are not in compliance with our policies and procedures, which, regardless of the ultimate outcome, may result in adverse publicity that could materially harm our brand, reputation and bus… |
| ZYMEWORKS-ROYALTY-LIMITED |
ZYMEWORKS-ROYALTY-LIMITED |
62%
|
he China National Medical Products Administration (“NMPA”) to seek approval for zanidatamab for the first-line treatment for HER2+ locally advanced or metastatic GEA, including cancers of the stomach… |
